` RNAC (Cartesian Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

RNAC
vs
S&P 500

Over the past 12 months, RNAC has underperformed S&P 500, delivering a return of -29% compared to the S&P 500's +13% growth.

Stocks Performance
RNAC vs S&P 500

Loading
RNAC
S&P 500
Add Stock

Performance Gap
RNAC vs S&P 500

Loading
RNAC
S&P 500
Difference
www.alphaspread.com

Performance By Year
RNAC vs S&P 500

Loading
RNAC
S&P 500
Add Stock

Competitors Performance
Cartesian Therapeutics Inc vs Peers

S&P 500
RNAC
ABBV
AMGN
GILD
VRTX
Add Stock

Cartesian Therapeutics Inc
Glance View

Market Cap
312.5m USD
Industry
Biotechnology

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The Company’s lead asset, Descartes-08, is an RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase IIb clinical development for patients with generalized myasthenia gravis. Descartes-08 is designed to be an autologous anti-BCMA rCAR-T. Descartes-08 is in clinical development for autoimmune diseases, including Myasthenia gravis (MG), a chronic autoimmune disorder that causes disabling muscle weakness and fatigue. Its proprietary technology platform, RNA Armory, is designed to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, including autologous, allogeneic, and in vivo transfection. Orphan Drug Designation by the United States Food and Drug Administration has granted Descartes-08 for the treatment of MG.

RNAC Intrinsic Value
0.18 USD
Overvaluation 99%
Intrinsic Value
Price
Back to Top